2.05
price up icon4.59%   0.09
after-market Handel nachbörslich: 2.05
loading
Schlusskurs vom Vortag:
$1.96
Offen:
$1.96
24-Stunden-Volumen:
131.93K
Relative Volume:
1.83
Marktkapitalisierung:
$43.11M
Einnahmen:
$48.20M
Nettoeinkommen (Verlust:
$-35.05M
KGV:
-1.308
EPS:
-1.5673
Netto-Cashflow:
$-13.02M
1W Leistung:
+6.77%
1M Leistung:
-2.84%
6M Leistung:
-1.44%
1J Leistung:
-35.74%
1-Tages-Spanne:
Value
$1.96
$2.2612
1-Wochen-Bereich:
Value
$1.80
$2.2612
52-Wochen-Spanne:
Value
$1.06
$5.22

Celularity Inc Stock (CELU) Company Profile

Name
Firmenname
Celularity Inc
Name
Telefon
(908) 768-2170
Name
Adresse
170 PARK AVE, FLORHAM PARK
Name
Mitarbeiter
123
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-04
Name
Neueste SEC-Einreichungen
Name
CELU's Discussions on Twitter

Vergleichen Sie CELU mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CELU
Celularity Inc
2.05 43.11M 48.20M -35.05M -13.02M -1.5673
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Celularity Inc Stock (CELU) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-01-30 Herabstufung Morgan Stanley Equal-Weight → Underweight
2022-12-22 Herabstufung Oppenheimer Outperform → Perform
2022-06-22 Eingeleitet H.C. Wainwright Buy
2022-04-06 Herabstufung Truist Buy → Hold
2022-01-28 Eingeleitet Oppenheimer Outperform
2021-11-24 Eingeleitet Morgan Stanley Equal-Weight
Alle ansehen

Celularity Inc Aktie (CELU) Neueste Nachrichten

pulisher
Jun 14, 2025

Two Sigma Investments LP Invests $93,000 in Celularity Inc. (NASDAQ:CELU) - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Celularity (NASDAQ:CELU) Shares Down 10.4% – Here’s Why - Defense World

Jun 12, 2025
pulisher
Jun 10, 2025

# Celularity terminates CFO, appoints interim replacement By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Celularity stock falls after CFO David Beers terminated By Investing.com - Investing.com Nigeria

Jun 10, 2025
pulisher
Jun 10, 2025

Celularity stock falls after CFO David Beers terminated - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

# Celularity terminates CFO, appoints interim replacement - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Celularity (CELU) Appoints Interim CFO After Terminating Current CFO | CELU Stock News - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Celularity Names Joseph DosSantos Interim CFO - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

Celularity Announces Chief Financial Officer Transition - marketscreener.com

Jun 10, 2025
pulisher
Jun 10, 2025

Celularity terminates CFO David Beers - TipRanks

Jun 10, 2025
pulisher
Jun 10, 2025

Celularity Announces Sudden CFO Departure, Taps Internal Talent and External Advisory Firm - Stock Titan

Jun 10, 2025
pulisher
Jun 03, 2025

Celularity announces publication on advancing ocular surface reconstruction - TipRanks

Jun 03, 2025
pulisher
Jun 02, 2025

Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Celularity (CELU) Advances Stem Cell Research with Innovative Bi - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Revolutionary Stem Cell Breakthrough: New Technology Could Transform Eye Disease Treatment - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

Celularity Receives Nasdaq Notice Regarding Form 10-Q - The Manila Times

May 31, 2025
pulisher
May 30, 2025

Celularity Inc. Notified by Nasdaq of Non-Compliance with Quarterly Filing Requirements - Nasdaq

May 30, 2025
pulisher
May 30, 2025

Celularity Gets 60 Days to Fix Nasdaq Compliance After Missing Q1 Filing Deadline - Stock Titan

May 30, 2025
pulisher
May 22, 2025

Reklaim Ltd. Reports Record 73% Revenue Growth in Q1 2025 and Launches Subscription Privacy Service - The Globe and Mail

May 22, 2025
pulisher
May 21, 2025

Celularity (NASDAQ:CELU) Trading 7.4% Higher – Here’s Why - Defense World

May 21, 2025
pulisher
May 20, 2025

Celularity extends debt maturity, issues stock to YA II PN By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

Celularity extends debt maturity, issues stock to YA II PN - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Celularity Extends Note Maturity with YA II PN - TipRanks

May 20, 2025
pulisher
May 14, 2025

Celularity Inc. Advances Placental-Derived Therapies - TipRanks

May 14, 2025
pulisher
May 09, 2025

Celularity (CELU) Reports Significant Revenue Growth in FY24 | C - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Celularity Announces Full Year 2024 Operating and Financial Results - The Manila Times

May 09, 2025
pulisher
May 09, 2025

Celularity Inc. Reports Strong Financial Growth and Increased Revenue for Year Ended December 31, 2024 - Nasdaq

May 09, 2025
pulisher
May 08, 2025

Celularity Inc SEC 10-K Report - TradingView

May 08, 2025
pulisher
May 02, 2025

Nvidia (NVDA) Targets Trillion Dollar Opportunity as Trump Ponders Lifting AI Chip Curbs - The Globe and Mail

May 02, 2025
pulisher
Apr 30, 2025

Should You Buy PayPal Stock on the Dip in May 2025? - The Globe and Mail

Apr 30, 2025
pulisher
Apr 29, 2025

The end of La Niña: Lessons about Plains wheat drought & why spring weather is bearish for most grain markets - The Globe and Mail

Apr 29, 2025
pulisher
Apr 28, 2025

Earnings To Watch: Caesars Entertainment (CZR) Reports Q1 Results Tomorrow - The Globe and Mail

Apr 28, 2025
pulisher
Apr 26, 2025

Celularity (CELU) Resolves Nasdaq Fee Issue to Avoid Delisting | - GuruFocus

Apr 26, 2025
pulisher
Apr 26, 2025

Celularity (NASDAQ:CELU) Stock Price Down 4.7% – Time to Sell? - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Celularity pays $70,000 fee to Nasdaq following receipt of notice - MSN

Apr 26, 2025
pulisher
Apr 26, 2025

Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees - The Manila Times

Apr 26, 2025
pulisher
Apr 25, 2025

Celularity Inc. Faces Potential Delisting from Nasdaq Due to Fee and Filing Delinquencies - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Celularity Given Until May 1 to Address Dual Nasdaq Compliance Issues or Face Delisting - Stock Titan

Apr 25, 2025
pulisher
Apr 24, 2025

Celularity faces Nasdaq delisting over late filing By Investing.com - Investing.com India

Apr 24, 2025
pulisher
Apr 23, 2025

Celularity faces Nasdaq delisting over late filing - Investing.com

Apr 23, 2025
pulisher
Apr 17, 2025

Looking for Exposure to Nvidia Stock? Try These Two ETFs - The Globe and Mail

Apr 17, 2025
pulisher
Apr 15, 2025

Markel Group to give a presentation at the beginning of its annual Omaha Brunch - The Globe and Mail

Apr 15, 2025
pulisher
Apr 14, 2025

Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products - The Manila Times

Apr 14, 2025
pulisher
Apr 14, 2025

CMS Extends Medicare Coverage for Wound Care Products: Major Win for Skin Substitute Market - Stock Titan

Apr 14, 2025
pulisher
Apr 07, 2025

Revolutionary NK Cell Therapy Shows Promise in Cancer Treatment: New Research Reveals - Stock Titan

Apr 07, 2025

Finanzdaten der Celularity Inc-Aktie (CELU)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Celularity Inc-Aktie (CELU) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Hariri Robert J
Chief Executive Officer
Apr 13 '25
Option Exercise
0.00
3,281
0
21,482
Haines John R
Senior Exec Vice President
Apr 13 '25
Option Exercise
0.00
1,641
0
29,698
Beers David C
Chief Financial Officer
Apr 13 '25
Option Exercise
0.00
1,025
0
18,561
Brigido Stephen
Pres., Functional Regeneration
Feb 17 '25
Option Exercise
0.00
10,000
0
11,641
Beers David C
Chief Financial Officer
Feb 17 '25
Option Exercise
0.00
12,500
0
21,932
Haines John R
Senior Exec Vice President
Feb 17 '25
Option Exercise
0.00
20,000
0
35,092
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):